



## Notice Regarding Bridge Loan Financing in Connection with an Additional Investment in ViiV Healthcare Ltd

**OSAKA, Japan, March 27, 2026** - Shionogi & Co., Ltd. (Head Office: Osaka, Japan; Chief Executive Officer: Isao Teshirogi, Ph.D.; hereafter "Shionogi") announced that "GSK, Pfizer and Shionogi agree on changes to ViiV Healthcare shareholding" on January 20, 2026<sup>1</sup>. With respect to this investment, we hereby announce that we have decided today to obtain a bridge loan and have entered into the related agreement.

### 1. Details of the Borrowing

(1) Lender	SUMITOMO MITSUI BANKING CORPORATION
(2) Amount Borrowed	JPY 300 billion
(3) Date of Agreement	March 27, 2026
(4) Loan Disbursement Date	March 31, 2026
(5) Interest Rate	Reference Interest Rate plus a spread
(6) Final Repayment Date	March 26, 2027
(7) Collateral	None

In addition, we announced that "Notice regarding the Bridge Loan Financing Related to Acquisition of Global Rights to Tanabe Pharma Corporation's RADICAVA ORS® (edaravone) and IV RADICAVA" on March 23, 2026<sup>2</sup>. Together with the present transaction, Shionogi has raised a total of JPY 660 billion through bridge loan financing.

### 2. Outlook

With respect to the funds to be raised under the borrowing agreement, Shionogi plans to refinance them into mid- to long-term financing by the repayment deadline.

### 3. Future Prospects

The impact on Shionogi's consolidated financial results for the fiscal year ending March 31, 2026, is expected to be minimal. The impact on the consolidated financial results for the fiscal year ending March 31, 2027, is currently being examined, and if any matters arise that should be disclosed, we will promptly disclose them.

### References

- [GSK, Pfizer and Shionogi agree on changes to ViiV Healthcare shareholding](#)
- [Notice regarding the Bridge Loan Financing Related to Acquisition of Global Rights to Tanabe Pharma Corporation's RADICAVA ORS® \(edaravone\) and IV RADICAVA](#)

**Forward-Looking Statements**

*This announcement contains forward-looking statements. These statements are based on expectations in light of the information currently available, assumptions that are subject to risks and uncertainties which could cause actual results to differ materially from these statements. Risks and uncertainties include general domestic and international economic conditions such as general industry and market conditions, and changes of interest rate and currency exchange rate. These risks and uncertainties particularly apply with respect to product-related forward-looking statements. Product risks and uncertainties include, but are not limited to, completion and discontinuation of clinical trials; obtaining regulatory approvals; claims and concerns about product safety and efficacy; technological advances; adverse outcome of important litigation; domestic and foreign healthcare reforms and changes of laws and regulations. Also for existing products, there are manufacturing and marketing risks, which include, but are not limited to, inability to build production capacity to meet demand, lack of availability of raw materials and entry of competitive products. The company disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise.*

**For Further Information, Contact:**

SHIONOGI Website Inquiry Form: <https://www.shionogi.com/global/en/contact.html>